PerpEquities

Equity

Viking Therapeutics, Inc. (VKTX) perpetual futures

VKTX perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade VKTXUSDT.

Viking Therapeutics is a clinical-stage biopharmaceutical company developing oral treatments for metabolic and endocrine conditions, including VK2809 for NASH and NAFLD and VK5211 for hip fracture recovery.

$34.85-3.2%NASDAQ open
Open in terminal

Price chart

Interactive TradingView chart

TradingView symbol NASDAQ:VKTX

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Trading data

Perpetual market activity

1/1 live markets
Venues
1
Live markets
1/1
24h volume
$9.6K
Open interest
$21.1K
Best liquidity
$59.5K
MEXC
Tightest spread
+14.4 bps
MEXC
Highest volume
$9.6K
MEXC
Settlement mix
USDT · 1/1
Perp/spot vol.
0.00x
Spot volume $473.2M
OI / float
0.00%
Float $4B
Spot performance
1D-3.24%
5D-14.85%
1M+10.57%
6M+9.35%
YTD+1.08%
1Y+37.78%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeVKTX/USDTTrading$34.85+12.6% APR
+0.012% every 8h
+14.4 bps$59.5K$9.6K$21.1KUSDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Thin liquidity · 1 of 1 venues absorb $10k · Typical cost: +28.7 bps

Cheapest execution: MEXC · +28.7 bps

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

VKTX

Tightest spread

VKTX

Highest volume

VKTX

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 2h ago
Market cap
$4.1B
Updated 2h ago
Revenue
$0
Trailing 12 months
Revenue growth
-
Next fiscal year
Profit margin
0.0%
P/E
-7.6
Peer P/E -5.0
Free cash flow
-$418.4M
Trailing 12 months
More metrics
Net income
-$534.8M
Trailing 12 months
P/S
-
Peer P/E
-5.0
Similar listed perps
Revenue estimate
$7.2M
Next fiscal year
Earnings
2026-10-28
Revenue est. - · Updated 2h ago
Dividend
-

Fundamental detail

Annual + quarterly
Latest revenue$0
Net margin0.0%
Free cash flow-$278.7M
Net debt-$165.7M
2020$0
2021$0
2022$0
2023$0
2024$0
2025$0
PeriodRevenueGrowthNet incomeFCF
2020$0--$39.5M-$21.8M
2021$0--$55M-$47.6M
2022$0--$68.9M-$48.4M
2023$0--$85.9M-$73.4M
2024$0--$110M-$87.8M
2025$0--$359.6M-$278.7M
PeriodGross marginOperating marginNet marginROEROA
20200.0%0.0%0.0%-16.2%-15.4%
20210.0%0.0%0.0%-27.2%-26.1%
20220.0%0.0%0.0%-47.4%-40.9%
20230.0%0.0%0.0%-24.7%-23.3%
20240.0%0.0%0.0%-12.5%-12.1%
20250.0%0.0%0.0%-56.3%-50.2%
PeriodCashDebtNet debtCurrent ratio
2020$29.1M$359K-$28.8M21.11
2021$26.4M$29K-$26.3M23.98
2022$36.6M$1.6M-$35.1M7.61
2023$55.5M$1.3M-$54.3M19.19
2024$26.7M$1.1M-$25.6M33.09
2025$165.8M$137K-$165.7M9.33
PeriodMarket capEnterprise valueP/SP/E
2020$408.7M$380M0.0-11.3
2021$355.1M$328.8M0.0-6.6
2022$722.2M$687.2M0.0-10.7
2023$1.8B$1.7B0.0-20.5
2024$4.4B$4.4B0.0-39.8
2025$4B$3.8B0.0-11.0
Q3 2024$0
Q4 2024$0
Q1 2025$0
Q2 2025$0
Q3 2025$0
Q4 2025$0
Q1 2026$0
Q2 2026$0
PeriodRevenueGrowthNet incomeFCF
Q3 2024$0--$24.9M-$22M
Q4 2024$0--$35.4M-$31.2M
Q1 2025$0--$45.6M-$52.3M
Q2 2025$0--$65.6M-$47.1M
Q3 2025$0--$90.8M-$94M
Q4 2025$0--$157.7M-$85.3M
Q1 2026$0--$158.3M-$114M
Q2 2026$0--$128M-$125.2M
PeriodGross marginOperating marginNet marginROEROA
Q3 20240.0%0.0%0.0%-2.7%-2.7%
Q4 20240.0%0.0%0.0%-4.0%-3.9%
Q1 20250.0%0.0%0.0%-5.4%-5.3%
Q2 20250.0%0.0%0.0%-8.2%-7.9%
Q3 20250.0%0.0%0.0%-12.7%-12.3%
Q4 20250.0%0.0%0.0%-24.7%-22.0%
Q1 20260.0%0.0%0.0%-31.5%-26.0%
Q2 20260.0%0.0%0.0%-31.4%-24.5%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$50.3M$1.2M-$49.1M36.47
Q4 2024$26.7M$1.1M-$25.6M33.09
Q1 2025$37.9M$1M-$36.9M44.25
Q2 2025$33.9M$878K-$33M25.86
Q3 2025$100.4M$755K-$99.6M28.34
Q4 2025$165.8M$137K-$165.7M9.33
Q1 2026$118.1M$0-$118.1M5.72
Q2 2026$125.8M$4.1M-$121.7M4.72
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$7B$7B0.0-71.9
Q4 2024$4.5B$4.5B0.0-31.4
Q1 2025$2.7B$2.7B0.0-14.7
Q2 2025$3B$2.9B0.0-11.4
Q3 2025$3B$2.9B0.0-8.1
Q4 2025$4B$3.8B0.0-6.4
Q1 2026$3.8B$3.6B0.0-5.9
Q2 2026$4.5B$4.4B0.0-8.9

Refreshed 2h ago

Charts: revenue, profit, cash flow & valuation
Revenue$0Q2 2026
Q3 2023: $0Q4 2023: $0Q1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0Q3 2023Q2 2026
Net income-$128MQ2 2026
-$118.7M-$79.2M-$39.6MQ3 2023: -$22.5MQ4 2023: -$24.6MQ1 2024: -$27.4MQ2 2024: -$22.3MQ3 2024: -$24.9MQ4 2024: -$35.4MQ1 2025: -$45.6MQ2 2025: -$65.6MQ3 2025: -$90.8MQ4 2025: -$157.7MQ1 2026: -$158.3MQ2 2026: -$128MQ3 2023Q2 2026
EBITDA-$127.9MQ2 2026
-$118.7M-$79.2M-$39.6MQ3 2023: -$22.5MQ4 2023: -$24.5MQ1 2024: -$27.3MQ2 2024: -$22.2MQ3 2024: -$24.8MQ4 2024: -$35.3MQ1 2025: -$45.5MQ2 2025: -$65.4MQ3 2025: -$90.7MQ4 2025: -$157.6MQ1 2026: -$158.3MQ2 2026: -$127.9MQ3 2023Q2 2026
Free cash flow-$125.2MQ2 2026
-$93.9M-$62.6M-$31.3MQ3 2023: -$19.7MQ4 2023: -$17.6MQ1 2024: -$6.1MQ2 2024: -$28.5MQ3 2024: -$22MQ4 2024: -$31.2MQ1 2025: -$52.3MQ2 2025: -$47.1MQ3 2025: -$94MQ4 2025: -$85.3MQ1 2026: -$114MQ2 2026: -$125.2MQ3 2023Q2 2026
EPS-$1.1Q2 2026
-$1.04-$0.69-$0.35Q3 2023: -$0.23Q4 2023: -$0.25Q1 2024: -$0.26Q2 2024: -$0.2Q3 2024: -$0.22Q4 2024: -$0.32Q1 2025: -$0.41Q2 2025: -$0.58Q3 2025: -$0.81Q4 2025: -$1.38Q1 2026: -$1.37Q2 2026: -$1.1Q3 2023Q2 2026
Cash / Debt$125.8MQ2 2026
$48.9M$97.8M$146.7M$195.6MQ3 2023 · Cash: $37.2MQ3 2023 · Debt: $1.3MQ4 2023 · Cash: $55.5MQ4 2023 · Debt: $1.3MQ1 2024 · Cash: $195.6MQ1 2024 · Debt: $1.2MQ2 2024 · Cash: $43.9MQ2 2024 · Debt: $1.1MQ3 2024 · Cash: $50.3MQ3 2024 · Debt: $1.2MQ4 2024 · Cash: $26.7MQ4 2024 · Debt: $1.1MQ1 2025 · Cash: $37.9MQ1 2025 · Debt: $1MQ2 2025 · Cash: $33.9MQ2 2025 · Debt: $878KQ3 2025 · Cash: $100.4MQ3 2025 · Debt: $755KQ4 2025 · Cash: $165.8MQ4 2025 · Debt: $137KQ1 2026 · Cash: $118.1MQ1 2026 · Debt: $0Q2 2026 · Cash: $125.8MQ2 2026 · Debt: $4.1MQ3 2023Q2 2026
CashDebt
Profitability0.0%Q2 2026
Q3 2023 · Gross margin: 0.0%Q4 2023 · Gross margin: 0.0%Q1 2024 · Gross margin: 0.0%Q2 2024 · Gross margin: 0.0%Q3 2024 · Gross margin: 0.0%Q4 2024 · Gross margin: 0.0%Q1 2025 · Gross margin: 0.0%Q2 2025 · Gross margin: 0.0%Q3 2025 · Gross margin: 0.0%Q4 2025 · Gross margin: 0.0%Q1 2026 · Gross margin: 0.0%Q2 2026 · Gross margin: 0.0%Q3 2023 · Operating margin: 0.0%Q4 2023 · Operating margin: 0.0%Q1 2024 · Operating margin: 0.0%Q2 2024 · Operating margin: 0.0%Q3 2024 · Operating margin: 0.0%Q4 2024 · Operating margin: 0.0%Q1 2025 · Operating margin: 0.0%Q2 2025 · Operating margin: 0.0%Q3 2025 · Operating margin: 0.0%Q4 2025 · Operating margin: 0.0%Q1 2026 · Operating margin: 0.0%Q2 2026 · Operating margin: 0.0%Q3 2023 · Net margin: 0.0%Q4 2023 · Net margin: 0.0%Q1 2024 · Net margin: 0.0%Q2 2024 · Net margin: 0.0%Q3 2024 · Net margin: 0.0%Q4 2024 · Net margin: 0.0%Q1 2025 · Net margin: 0.0%Q2 2025 · Net margin: 0.0%Q3 2025 · Net margin: 0.0%Q4 2025 · Net margin: 0.0%Q1 2026 · Net margin: 0.0%Q2 2026 · Net margin: 0.0%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Shares outstanding115.9MQ2 2026
29M58M86.9M115.9MQ3 2023: 99.8MQ4 2023: 100.1MQ1 2024: 103.5MQ2 2024: 110.4MQ3 2024: 110.9MQ4 2024: 111.3MQ1 2025: 112.1MQ2 2025: 112.1MQ3 2025: 112.3MQ4 2025: 114MQ1 2026: 115.6MQ2 2026: 115.9MQ3 2023Q2 2026
Valuation-8.9Q2 2026
-57.3-38.2-19.1Q3 2023 · P/E: -12.0Q4 2023 · P/E: -18.6Q1 2024 · P/E: -76.4Q2 2024 · P/E: -69.1Q3 2024 · P/E: -71.9Q4 2024 · P/E: -31.4Q1 2025 · P/E: -14.7Q2 2025 · P/E: -11.4Q3 2025 · P/E: -8.1Q4 2025 · P/E: -6.4Q1 2026 · P/E: -5.9Q2 2026 · P/E: -8.9Q3 2023 · P/S: 0.0Q4 2023 · P/S: 0.0Q1 2024 · P/S: 0.0Q2 2024 · P/S: 0.0Q3 2024 · P/S: 0.0Q4 2024 · P/S: 0.0Q1 2025 · P/S: 0.0Q2 2025 · P/S: 0.0Q3 2025 · P/S: 0.0Q4 2025 · P/S: 0.0Q1 2026 · P/S: 0.0Q2 2026 · P/S: 0.0Q3 2023Q2 2026
P/EP/S
Revenue$02025
2018: $02019: $02020: $02021: $02022: $02023: $02024: $02025: $020182025
Net income-$359.6M2025
-$269.7M-$179.8M-$89.9M2018: -$22.1M2019: -$25.8M2020: -$39.5M2021: -$55M2022: -$68.9M2023: -$85.9M2024: -$110M2025: -$359.6M20182025
EBITDA-$359.2M2025
-$268.2M-$177.2M-$86.3M$4.7M2018: $4.7M2019: -$25.4M2020: -$39.1M2021: -$54.7M2022: -$68.5M2023: -$85.5M2024: -$109.5M2025: -$359.2M20182025
Free cash flow-$278.7M2025
-$209M-$139.3M-$69.7M2018: -$18.8M2019: -$24.8M2020: -$21.8M2021: -$47.6M2022: -$48.4M2023: -$73.4M2024: -$87.8M2025: -$278.7M20182025
EPS-$3.192025
-$2.39-$1.6-$0.82018: -$0.382019: -$0.362020: -$0.52021: -$0.72022: -$0.882023: -$0.912024: -$1.012025: -$3.1920182025
Cash / Debt$165.8M2025
$41.5M$82.9M$124.4M$165.8M2018 · Cash: $24.8M2018 · Debt: $02019 · Cash: $8.4M2019 · Debt: $662K2020 · Cash: $29.1M2020 · Debt: $359K2021 · Cash: $26.4M2021 · Debt: $29K2022 · Cash: $36.6M2022 · Debt: $1.6M2023 · Cash: $55.5M2023 · Debt: $1.3M2024 · Cash: $26.7M2024 · Debt: $1.1M2025 · Cash: $165.8M2025 · Debt: $137K20182025
CashDebt
Profitability0.0%2025
2018 · Gross margin: 0.0%2019 · Gross margin: 0.0%2020 · Gross margin: 0.0%2021 · Gross margin: 0.0%2022 · Gross margin: 0.0%2023 · Gross margin: 0.0%2024 · Gross margin: 0.0%2025 · Gross margin: 0.0%2018 · Operating margin: 0.0%2019 · Operating margin: 0.0%2020 · Operating margin: 0.0%2021 · Operating margin: 0.0%2022 · Operating margin: 0.0%2023 · Operating margin: 0.0%2024 · Operating margin: 0.0%2025 · Operating margin: 0.0%2018 · Net margin: 0.0%2019 · Net margin: 0.0%2020 · Net margin: 0.0%2021 · Net margin: 0.0%2022 · Net margin: 0.0%2023 · Net margin: 0.0%2024 · Net margin: 0.0%2025 · Net margin: 0.0%20182025
Gross marginOperating marginNet margin
Shares outstanding112.7M2025
28.2M56.3M84.5M112.7M2018: 57.6M2019: 72M2020: 72.6M2021: 77.2M2022: 76.8M2023: 94.3M2024: 109M2025: 112.7M20182025
Valuation-11.02025
-29.9-19.9-10.02018 · P/E: -20.12019 · P/E: -22.32020 · P/E: -11.32021 · P/E: -6.62022 · P/E: -10.72023 · P/E: -20.52024 · P/E: -39.82025 · P/E: -11.02018 · P/S: 0.02019 · P/S: 0.02020 · P/S: 0.02021 · P/S: 0.02022 · P/S: 0.02023 · P/S: 0.02024 · P/S: 0.02025 · P/S: 0.020182025
P/EP/S

Next catalyst

Catalysts

Earnings
2026-10-28
Revenue est. - · Updated 2h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-4.61$7.2M-14
FY 2027-4.39$7.3M-14
FY 2028-3.55$183.8M-14
FY 2029-1.23$489.6M-7
FY 20302.58$1.2B-11
Q1 2027-1.01$0-5

Company events

6
2026-10-28EarningsActual - / Estimate -1.07-
2026-07-29EarningsActual -1.1 / Estimate -1.23Beat
2026-04-29EarningsActual -1.37 / Estimate -1.01Miss
2026-02-11EarningsActual -1.38 / Estimate -0.89Miss
2025-10-22EarningsActual -0.81 / Estimate -0.7Miss
2025-07-23EarningsActual -0.58 / Estimate -0.44Miss

Peer comparison

Similar listed perps

Analyst track record

How the analysts covering VKTX have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings98343
Analysts2327
Buy / hold / sell96 / 2 / 0334 / 9 / 0
Upgrades / downgrades / initiations0 / 0 / 40 / 0 / 13
Price targets hit / missed0 / 81 (0%)17 / 266 (6%)
Avg. return after a rating (TipRanks)-60.1%-55.5%
Best / worst call-6.4% / -71.6%+27.0% / -78.3%

After buy calls on this stock: not enough measured cases yet

Latest ratings

DateAnalystCallTarget
Sep 22, 2026Naz RahmanMaxim GroupBuyReiterated$70.00
Sep 23, 2026Unknown AnalystLeerink PartnersBuyReiterated$118
Sep 23, 2026Roger SongJefferiesBuyMaintained$101
Sep 23, 2026Daniel BrimsLake StreetBuyReiterated$89.00
Sep 22, 2026Richard Law CFAGoldman SachsHoldMaintained$38.00

TipRanks data via FMP · computed Sep 28, 2026 · 98 ratings

Frequently asked questions

Where can I trade VKTX perpetual futures?

Viking Therapeutics, Inc. (VKTX) perpetual futures trade on 1 crypto venues, including MEXC. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade VKTX around the clock?

Yes. Unlike the underlying stock, VKTX perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on VKTX perpetuals?

Right now the VKTX perp funding rate is +12.6% annualized (venue median), ranging from +12.6% to +12.6% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the VKTX perp price compare to the Viking Therapeutics, Inc. stock?

The venue-median VKTX perp mark is $34.9 versus a reference stock price of $34.9, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a VKTX perpetual future?

A VKTX perpetual is a derivative that tracks the price of Viking Therapeutics, Inc. with no expiry date. It lets you take long or short exposure to Viking Therapeutics, Inc. on crypto venues, around the clock.

What is VKTXUSDT perpetual?

VKTXUSDT is the symbol most crypto exchanges use for the Viking Therapeutics, Inc. perpetual settled in USDT (Tether). It tracks the VKTX share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

VKTX perpetuals · perpequities.comVKTX perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/vktx-perp"><img src="https://perpequities.com/badge/vktx-perp.svg" width="240" height="64" alt="VKTX perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of VKTX perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for VKTX — one email every Sunday.

Watchlist and alerts

Price and funding alerts for VKTX, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X